Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study

NCT02511353 | Completed Phase 2 DMC

• 3 other identifiers: 14.00227756720
• Study Type: interventional
• Target: 141
• Locations: 1 country
• Sites: 1

Brief Summary

In western Kenya the prevalence of malaria in \<5 year olds has fallen from 70% in 1997 to 40% in 2008, where it has now stagnated. Innovative approaches are needed to continue towards elimination. Ivermectin is a broad spectrum antiparasitic endectocide widely used for the control of onchocerciasis and lymphatic filariasis at a dose of 150-200 mcg/kg. Ivermectin at this dose has a potent, but short-lived effect for 6-11 days on mosquito survival, egg-laying, and parasite sporogony. Higher doses are needed to prolong its mosquitocidal effects. Previous studies have shown ivermectin is very well tolerated and safe even up to 2,000 mcg/kg. This dose finding study will evaluate the transmission blocking effect of high-dose ivermectin to define the optimal dose for future use of ivermectin in combination with artemisinin-based combination therapy (ACT) for mass drug administration (MDA). It explores a research question of global relevance. A prolonged transmission blocking effect of ivermectin could have substantial consequences for malaria control in the next decades. The results are expected to inform national malaria control programs in malaria endemic countries, to inform WHO guidelines, and to contribute to the regulatory process.

Conditions

Malaria

Keywords

malaria; plasmodium; dihydroartemisinin-piperaquine; ivermectin

Outcome Measures

Primary Outcomes (1)

• Mosquito survival

  Survival of mosquitoes at 14 days after feeding on blood taking from study participants who started the 3-day ivermectin and DP regimen 7 days earlier.

Secondary Outcomes (12)

• Mosquito survival

  Survival of mosquitoes at each day up to day 21 or 28 after each feeding experiments performed at 0, 2 day+4h, 10, 14, 21, 28 days after start of treatment.

• Number of patients with malaria clinical and parasitological treatment response

  Up to day 28.

• Area under the plasma concentration versus time curve (AUC) of ivermectin

  Up to day 28.

• Area under the plasma concentration versus time curve (AUC) of piperaquine

  Up to day 28.

• Peak plasma Concentration (Cmax) of ivermectin

  Up to day 28.

Study Arms (3)

placebo

PLACEBO COMPARATOR

Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: placebo 600 mcg/kg/day.

Drug: placebo; Drug: dihydroartemisinin-piperaquine

ivermectin 300 mcg/kg

EXPERIMENTAL

Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: ivermectin 300 mcg/kg/day and placebo 300 mcg/kg/day.

Drug: ivermectin; Drug: placebo; Drug: dihydroartemisinin-piperaquine

ivermectin 600 mcg/kg

EXPERIMENTAL

Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: ivermectin 600 mcg/kg/day.

Drug: ivermectin; Drug: dihydroartemisinin-piperaquine

Interventions

ivermectin DRUG

ivermectin 300 mcg/kg; ivermectin 600 mcg/kg

placebo DRUG

Placebo for ivermectin.

ivermectin 300 mcg/kg; placebo

dihydroartemisinin-piperaquine DRUG

ivermectin 300 mcg/kg; ivermectin 600 mcg/kg; placebo

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Symptomatic, uncomplicated Plasmodium falciparum infection
• Positive malaria microscopy or malaria RDT (pLDH)
• Age: 18-50 years
• Provide written informed consent
• Agree to be able to travel to clinic on days: 1, 2, 7, 10, 14, 21, and 28

You may not qualify if:

• Signs or symptoms of severe malaria
• Unable to provide written informed consent
• For women: pregnancy or lactation
• Hypersensitivity to ivermectin or DP
• QTc \>460 ms on ECG
• Body Mass Index (BMI) below 16 or above 32 kg/m2
• Haemoglobin concentration below 9 g/dL
• Taken ivermectin in the last month
• Taken dihydroartemisinin-piperaquine in the last 12 weeks
• Loa loa as assessed by travel history to Angola, Cameroon, Chad, Central African Republic, Congo, DR Congo, Equatorial Guinea, Ethiopia, Gabon, Nigeria and Sudan
• History and/or symptoms indicating chronic illness
• Current use of tuberculosis or anti-retroviral medication
• Previously enrolled in the same study

Sponsors & Collaborators

• Liverpool School of Tropical Medicine: lead
• Kenya Medical Research Institute: collaborator
• Centers for Disease Control and Prevention: collaborator

Study Sites (1)

Jaramogi Oginga Odinga Teaching and Referral Hospital

Kisumu, 40100, Kenya

Location

Related Publications (4)

• Smit MR, Ochomo E, Aljayyoussi G, Kwambai T, Abong'o B, Bayoh N, Gimnig J, Samuels A, Desai M, Phillips-Howard PA, Kariuki S, Wang D, Ward S, Ter Kuile FO. Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya. JMIR Res Protoc. 2016 Nov 17;5(4):e213. doi: 10.2196/resprot.6617.

  PMID: 27856406 BACKGROUND

• Smit MR, Ochomo EO, Aljayyoussi G, Kwambai TK, Abong'o BO, Chen T, Bousema T, Slater HC, Waterhouse D, Bayoh NM, Gimnig JE, Samuels AM, Desai MR, Phillips-Howard PA, Kariuki SK, Wang D, Ward SA, Ter Kuile FO. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2018 Jun;18(6):615-626. doi: 10.1016/S1473-3099(18)30163-4. Epub 2018 Mar 27.

  PMID: 29602751 RESULT

• Smit MR, Ochomo EO, Waterhouse D, Kwambai TK, Abong'o BO, Bousema T, Bayoh NM, Gimnig JE, Samuels AM, Desai MR, Phillips-Howard PA, Kariuki SK, Wang D, Ter Kuile FO, Ward SA, Aljayyoussi G. Pharmacokinetics-Pharmacodynamics of High-Dose Ivermectin with Dihydroartemisinin-Piperaquine on Mosquitocidal Activity and QT-Prolongation (IVERMAL). Clin Pharmacol Ther. 2019 Feb;105(2):388-401. doi: 10.1002/cpt.1219. Epub 2018 Oct 9.

  PMID: 30125353 RESULT

• Smit MR, Ochomo EO, Aljayyoussi G, Kwambai TK, Abong'o BO, Bousema T, Waterhouse D, Bayoh NM, Gimnig JE, Samuels AM, Desai MR, Phillips-Howard PA, Kariuki SK, Wang D, Ward SA, Ter Kuile FO. Human Direct Skin Feeding Versus Membrane Feeding to Assess the Mosquitocidal Efficacy of High-Dose Ivermectin (IVERMAL Trial). Clin Infect Dis. 2019 Sep 13;69(7):1112-1119. doi: 10.1093/cid/ciy1063.

  PMID: 30590537 DERIVED

MeSH Terms

Conditions

Malaria

Interventions

Ivermectin

Condition Hierarchy (Ancestors)

Protozoan Infections; Parasitic Diseases; Infections; Mosquito-Borne Diseases; Vector Borne Diseases

Intervention Hierarchy (Ancestors)

Macrolides; Polyketides; Lactones; Organic Chemicals

Study Officials

• Menno R. Smit, MD, MPH

  Liverpool School of Tropical Medicine

  PRINCIPAL INVESTIGATOR

• Feiko ter Kuile, Prof.

  Liverpool School of Tropical Medicine

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 15, 2015
• First Posted: July 30, 2015
• Study Start: July 1, 2015
• Primary Completion: July 1, 2016
• Study Completion: July 1, 2016
• Last Updated: August 23, 2018

Record last verified: 2018-08

Locations

KE (1)